AKERO THEREP.INC.DL-0001 (0K4 F) stock market data APIs
€43.4678
0(0%)
as of July 10, 2025
Try our APIs with
free plan!
AKERO THEREP.INC.DL-0001 Financial Data Overview
Price chart is built with
Anychart
Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Prev. Close
43.4678
Open
43.4678
High
43.4678
Low
43.4678
52 wk Range
21.19-55.1
Market Cap
3 522 M
Shares Outstanding
79 718 K
EPS
-0.83
Beta
-0.16
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get AKERO THEREP.INC.DL-0001 data using free add-ons & libraries
Get AKERO THEREP.INC.DL-0001 Fundamental Data
AKERO THEREP.INC.DL-0001 Fundamental data includes:
- Net Revenue:
- EBITDA: -306 329 504
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-06-30
- EPS/Forecast: -0.72
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
AKERO THEREP.INC.DL-0001 News
New
Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for p...
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for pa...
Why Akero Therapeutics, Inc. (AKRO) Skyrocketed Today
We recently published a list of These 10 Firms Just Beat the Market Today. In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands against other stocks tha...
Why Akero Therapeutics (AKRO) Is Among the Best Performing Healthcare Stocks to Buy Now
We recently published a list of 11 Best Performing Healthcare Stocks to Buy Now. In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands against other best ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
